Dextall | $15,000,000 | (Jul 15, 2025)
Duranta | $7,000,000 | (Jul 15, 2025)
Circuit(US) | $4,500,000 | (Jul 15, 2025)
Certified by Founder
Lodge
Volastra Therapeutics
start up
United States
- New York, New York
- 08/03/2023
- Series A
- $60,000,000
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune activating pipeline.
- Industry Biotechnology
- Website https://www.volastratx.com/
- LinkedIn https://www.linkedin.com/company/volastra-therapeutics/people/
ScienceMachine | $3,500,000 | (Jul 15, 2025)
Bastazo | $5,300,000 | (Jul 15, 2025)
Illimis Therapeutics | $42,000,000 | (Jul 15, 2025)
Helios | $4,000,000 | (Jul 15, 2025)
GenPhoenix | $15,000,000 | (Jul 15, 2025)
Asepha | $4,000,000 | (Jul 15, 2025)
Moonvalley | $84,000,000 | (Jul 15, 2025)
MOTOR Ai | $20,000,000 | (Jul 15, 2025)
Cogent Security | $11,000,000 | (Jul 15, 2025)